Liver function may affect how body handles new antifungal drug

NCT ID NCT05582187

Completed Knowledge-focused Sponsor: Basilea Pharmaceutica Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how a single dose of the antifungal drug fosmanogepix is processed in the bodies of 28 adults with varying degrees of liver impairment. Participants took one pill by mouth, and researchers measured drug levels in the blood over time. The goal was to see if liver function changes how the drug is absorbed and cleared, which could help guide safe dosing for patients with liver problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fosmanogepix (a single oral dose)
What this could lead to: If successful, this study could help doctors determine the right dose of fosmanogepix for patients with liver problems, making the drug safer and more effective.
What could go wrong: This is a very early, small study (28 people) focused on drug processing, not on treating a disease. Results may not apply to real-world use, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATIC IMPAIRMENT

Contacts and locations

Locations

Genesis Clinical Research, LLC

Tampa, Florida, 33603, United States
Inland Empire Liver Foundation

Rialto, California, 92337, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.